NeoGenomics Statistics

Total Valuation

NeoGenomics has a market cap or net worth of $1.89 billion. The enterprise value is $2.03 billion.

Market Cap	1.89B
Enterprise Value	2.03B

Important Dates

The next confirmed earnings date is Tuesday, November 5, 2024, before market open.

Earnings Date	Nov 5, 2024
Ex-Dividend Date	n/a

Share Statistics

NeoGenomics has 128.16 million shares outstanding. The number of shares has increased by 0.93% in one year.

Current Share Class	128.16M
Shares Outstanding	128.16M
Shares Change (YoY)	+0.93%
Shares Change (QoQ)	+0.43%
Owned by Insiders (%)	1.32%
Owned by Institutions (%)	98.19%
Float	126.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	91.05
PS Ratio	2.77
Forward PS	2.61
PB Ratio	1.98
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.67.

Current Ratio	1.99
Quick Ratio	1.82
Debt / Equity	0.67
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-12.77

Financial Efficiency

Return on equity (ROE) is -8.38% and return on invested capital (ROIC) is -3.47%.

Return on Equity (ROE)	-8.38%
Return on Assets (ROA)	-3.21%
Return on Capital (ROIC)	-3.47%
Revenue Per Employee	$306,723
Profits Per Employee	-$37,013
Employee Count	2,100
Asset Turnover	0.39
Inventory Turnover	14.99

Taxes

Income Tax	-2.11M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.40% in the last 52 weeks. The beta is 1.18, so NeoGenomics's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	-7.40%
50-Day Moving Average	14.75
200-Day Moving Average	14.86
Relative Strength Index (RSI)	53.94
Average Volume (20 Days)	770,070

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoGenomics had revenue of $644.12 million and -$77.73 million in losses. Loss per share was -$0.62.

Revenue	644.12M
Gross Profit	280.43M
Operating Income	-85.22M
Pretax Income	-83.44M
Net Income	-77.73M
EBITDA	-12.50M
EBIT	-85.22M
Loss Per Share	-$0.62

Full Income Statement

Balance Sheet

The company has $387.81 million in cash and $606.27 million in debt, giving a net cash position of -$218.46 million or -$1.70 per share.

Cash & Cash Equivalents	387.81M
Total Debt	606.27M
Net Cash	-218.46M
Net Cash Per Share	-$1.70
Equity (Book Value)	908.21M
Book Value Per Share	7.15
Working Capital	293.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $15.01 million and capital expenditures -$36.52 million, giving a free cash flow of -$21.51 million.

Operating Cash Flow	15.01M
Capital Expenditures	-36.52M
Free Cash Flow	-21.51M
FCF Per Share	-$0.17

Full Cash Flow Statement

Margins

Gross margin is 43.54%, with operating and profit margins of -13.23% and -12.07%.

Gross Margin	43.54%
Operating Margin	-13.23%
Pretax Margin	-12.39%
Profit Margin	-12.07%
EBITDA Margin	-1.94%
EBIT Margin	-13.23%
FCF Margin	-4.73%

Dividends & Yields

NeoGenomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.93%
Shareholder Yield	-0.93%
Earnings Yield	-4.29%
FCF Yield	-1.19%

Dividend Details

Analyst Forecast

The average price target for NeoGenomics is $19.89, which is 35.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$19.89
Price Target Difference	35.17%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on April 16, 2003. It was a reverse split with a ratio of 0.01:1.

Last Split Date	Apr 16, 2003
Split Type	Reverse
Split Ratio	0.01:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	5